Trial Profile
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2018
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms FREEDOM-3S
- Sponsors Intarcia Therapeutics
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 19 Oct 2017 Status changed from active, no longer recruiting to completed.